Expression of prothymosin α in lung cancer is associated with squamous cell carcinoma and smoking

  • Authors:
    • Yu‑Hsuan Kuo
    • Ai‑Li Shiau
    • Chao‑Ling Tung
    • Yu‑Chu Su
    • Chien‑Feng Li
    • Bing‑Hua Su
    • Chao‑Jung Tsao
    • Chao‑Liang Wu
    • Yin‑Hsun Feng
    • Pensee Wu
  • View Affiliations

  • Published online on: April 12, 2019     https://doi.org/10.3892/ol.2019.10248
  • Pages: 5740-5746
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Prothymosin α (ProTα) is a nuclear protein that serves a role in oncogenesis, by promoting proliferation and inhibiting apoptosis in various malignancies. The present study was designed to investigate ProTα expression in resected human non‑small cell lung cancer to define the clinicopathological associations of ProTα‑positive lung cancer. Immunohistochemical staining of ProTα was performed using tumor sample slides from 149 patients with non‑small cell lung cancer, who underwent surgical resection. Association between the expression of ProTα and the following clinicopathological parameters was accessed: Age, sex, stage, lymph node involvement, pathological subtype, recurrence and cigarette smoking. A total of 85 tumors (57%) were classified as ProTα‑positive lung cancer by staining intensity and 73 tumors (49%) were regarded as ProTα‑positive by scoring index. The majority of patients with ProTα‑positive tumors were younger (P=0.05) and had squamous cell carcinoma (P<0.01) compared with older and adenocarcinoma. Positive expression of ProTα by staining intensity was associated with a higher incidence rate of cancer recurrence (P=0.05) compared with negative ProTα expression. ProTα was also associated with cigarette smoking, particularly in the group with squamous cell carcinoma. Therefore, the present data suggested that ProTα‑positive non‑small cell lung cancer was associated with younger patients, squamous cell carcinoma, cigarette smoking and a higher incidence recurrence rate, subsequently indicating a subtype consisting of patients with smoking‑associated inferior outcomes.

References

1 

Haritos AA, Goodall GJ and Horecker BL: Prothymosin alpha: Isolation and properties of the major immunoreactive form of thymosin alpha 1 in rat thymus. Proc Natl Acad Sci U S A. 81:1008–1011. 1984. View Article : Google Scholar : PubMed/NCBI

2 

Smith MR, al-Katib A, Mohammad R, Silverman A, Szabo P, Khilnani S, Kohler W, Nath R and Mutchnick MG: Prothymosin alpha gene expression correlates with proliferation, not differentiation, of HL-60 cells. Blood. 82:1127–1132. 1993.PubMed/NCBI

3 

Jiang X, Kim HE, Shu H, Zhao Y, Zhang H, Kofron J, Donnelly J, Burns D, Ng SC, Rosenberg S and Wang X: Distinctive roles of PHAP proteins and prothymosin-alpha in a death regulatory pathway. Science. 299:223–226. 2003. View Article : Google Scholar : PubMed/NCBI

4 

Pai CW and Chen YH: Transgenic expression of prothymosin alpha on zebrafish epidermal cells promotes proliferation and attenuates UVB-induced apoptosis. Transgenic Res. 19:655–665. 2010. View Article : Google Scholar : PubMed/NCBI

5 

Letsas KP and Frangou-Lazaridis M: Surfing on prothymosin alpha proliferation and anti-apoptotic properties. Neoplasma. 53:92–96. 2006.PubMed/NCBI

6 

Mori M, Barnard GF, Staniunas RJ, Jessup JM, Steele GD Jr and Chen LB: Prothymosin-alpha mRNA expression correlates with that of c-myc in human colon cancer. Oncogene. 8:2821–2826. 1993.PubMed/NCBI

7 

Jou YC, Tung CL, Tsai YS, Shen CH, Syue-Yi C, Shiau AL, Tsai HT, Wu CL and Tzai TS: Prognostic relevance of prothymosin-alpha expression in human upper urinary tract transitional cell carcinoma. Urology. 74:951–957. 2009. View Article : Google Scholar : PubMed/NCBI

8 

Tripathi SC, Matta A, Kaur J, Grigull J, Chauhan SS, Thakar A, Shukla NK, Duggal R, Choudhary AR, Dattagupta S, et al: Overexpression of prothymosin alpha predicts poor disease outcome in head and neck cancer. PLoS One. 6:e192132011. View Article : Google Scholar : PubMed/NCBI

9 

Ha SY, Song DH, Hwang SH, Cho SY and Park CK: Expression of prothymosin alpha predicts early recurrence and poor prognosis of hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int. 14:171–177. 2015. View Article : Google Scholar : PubMed/NCBI

10 

Zhang M, Cui F, Lu S, Lu H, Jiang T, Chen J, Zhang X, Jin Y, Peng Z and Tang H: Increased expression of prothymosin-α, independently or combined with TP53, correlates with poor prognosis in colorectal cancer. Int J Clin Exp Pathol. 7:4867–4876. 2014.PubMed/NCBI

11 

Sasaki H, Fujii Y, Masaoka A, Yamakawa Y, Fukai I, Kiriyama M, Saito Y and Matsui H: Elevated plasma thymosin-alpha1 levels in lung cancer patients. Eur J Cardiothorac Surg. 12:885–891. 1997. View Article : Google Scholar : PubMed/NCBI

12 

Moody TW, Leyton J, Zia F, Tuthill C, Badamchian M and Goldstein AL: Thymosinalpha1 is chemopreventive for lung adenoma formation in A/J mice. Cancer Lett. 155:121–127. 2000. View Article : Google Scholar : PubMed/NCBI

13 

Sasaki H, Nonaka M, Fujii Y, Yamakawa Y, Fukai I, Kiriyama M and Sasaki M: Expression of the prothymosin-a gene as a prognostic factor in lung cancer. Surg Today. 31:936–938. 2001. View Article : Google Scholar : PubMed/NCBI

14 

Su BH, Tseng YL, Shieh GS, Chen YC, Shiang YC, Wu P, Li KJ, Yen TH, Shiau AL and Wu CL: Prothymosin α overexpression contributes to the development of pulmonary emphysema. Nat Commun. 4:19062013. View Article : Google Scholar : PubMed/NCBI

15 

Sukhacheva EA, Evstafieva AG, Fateeva TV, Shakulov VR, Efimova NA, Karapetian RN, Rubtsov YP and Vartapetian AB: Sensing prothymosin alpha origin, mutations and conformation with monoclonal antibodies. J Immunol Methods. 266:185–196. 2002. View Article : Google Scholar : PubMed/NCBI

16 

Tsai YS, Jou YC, Lee GF, Chen YC, Shiau AL, Tsai HT, Wu CL and Tzai TS: Aberrant prothymosin-alpha expression in human bladder cancer. Urology. 73:188–192. 2009. View Article : Google Scholar : PubMed/NCBI

17 

Greene FL, Page DL, Fleming ID, Fritz AG, Balch CM, Haller DG and Morrow M: AJCC Cancer Staging Manual. 6th. Springer Publ. Corp.; New York, NY: pp. 165–178. 2002

18 

Pesch B, Kendzia B, Gustavsson P, Jöckel KH, Johnen G, Pohlabeln H, Olsson A, Ahrens W, Gross IM, Brüske I, et al: Cigarette smoking and lung cancer-Relative risk estimates for the major histological types from a pooled analysis of case-control studies. Int J Cancer. 131:1210–1219. 2012. View Article : Google Scholar : PubMed/NCBI

19 

Ralhan R, Desouza LV, Matta A, Tripathi SC, Ghanny S, Datta Gupta S, Bahadur S and Siu KW: Discovery and verification of head-and-neck cancer biomarkers by differential protein expression analysis using iTRAQ labeling, multidimensional liquid chromatography, and tandem mass spectrometry. Mol Cell Proteomics. 7:1162–1173. 2008. View Article : Google Scholar : PubMed/NCBI

20 

Magdalena C, Dominguez F, Loidi L and Puente JL: Tumour prothymosin alpha content, a potential prognostic marker for primary breast cancer. Br J Cancer. 82:584–590. 2000. View Article : Google Scholar : PubMed/NCBI

21 

Wu CG, Habib NA, Mitry RR, Reitsma PH, van Deventer SJ and Chamuleau RA: Overexpression of hepatic prothymosin alpha, a novel marker for human hepatocellular carcinoma. Br J Cancer. 76:1199–1204. 1997. View Article : Google Scholar : PubMed/NCBI

22 

Leys CM, Nomura S, LaFleur BJ, Ferrone S, Kaminishi M, Montgomery E and Goldenring JR: Expression and prognostic significance of prothymosin-alpha and ERp57 in human gastric cancer. Surgery. 141:41–50. 2007. View Article : Google Scholar : PubMed/NCBI

23 

Suzuki S, Takahashi S, Takahashi S, Takeshita K, Hikosaka A, Wakita T, Nishiyama N, Fujita T, Okamura T and Shirai T: Expression of prothymosin alpha is correlated with development and progression in human prostate cancers. Prostate. 66:463–469. 2006. View Article : Google Scholar : PubMed/NCBI

24 

Su BH, Tseng YL, Shieh GS, Chen YC, Wu P, Shiau AL and Wu CL: Over-expression of prothymosin-α antagonizes TGFβ signalling to promote the development of emphysema. J Pathol. 238:412–422. 2016. View Article : Google Scholar : PubMed/NCBI

25 

Chauhan SS, Kaur J, Kumar M, Matta A, Srivastava G, Alyass A, Assi J, Leong I, MacMillan C, Witterick I, et al: Prediction of recurrence-free survival using a protein expression-based risk classifier for head and neck cancer. Oncogenesis. 4:e1472015. View Article : Google Scholar : PubMed/NCBI

26 

Gou LT, Tong AP, Yan F, Yuan Z, He F, Wang W, Zhou Y, Chen LJ, Tang MH and Yang JL: Altered protein-expressing profile in hPNAS4-induced apoptosis in A549 human lung adenocarcinoma cells. J Cell Biochem. 108:1211–1219. 2009. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

June 2019
Volume 17 Issue 6

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Kuo, Y., Shiau, A., Tung, C., Su, Y., Li, C., Su, B. ... Wu, P. (2019). Expression of prothymosin α in lung cancer is associated with squamous cell carcinoma and smoking. Oncology Letters, 17, 5740-5746. https://doi.org/10.3892/ol.2019.10248
MLA
Kuo, Y., Shiau, A., Tung, C., Su, Y., Li, C., Su, B., Tsao, C., Wu, C., Feng, Y., Wu, P."Expression of prothymosin α in lung cancer is associated with squamous cell carcinoma and smoking". Oncology Letters 17.6 (2019): 5740-5746.
Chicago
Kuo, Y., Shiau, A., Tung, C., Su, Y., Li, C., Su, B., Tsao, C., Wu, C., Feng, Y., Wu, P."Expression of prothymosin α in lung cancer is associated with squamous cell carcinoma and smoking". Oncology Letters 17, no. 6 (2019): 5740-5746. https://doi.org/10.3892/ol.2019.10248